Parexel has received $100m from the sale of notes with a group of institutional investors as part of plans to finance new acquisitions and pay down outstanding debt.
There are currently three key market trends that play to Parexel's
strengths and one of them is the globalisation of clinical trials,
the company's CEO claimed during a healthcare conference earlier
this month.